Cargando…
Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Despite good responses to standard of care frontline chemoimmunotherapy, the prognosis of relapsed/refractory (R/R) patients remains obscured by the possible inadequate responses to salvage therapy, eligibi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Atlantis Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432323/ https://www.ncbi.nlm.nih.gov/pubmed/34595463 http://dx.doi.org/10.2991/chi.k.210305.001 |
_version_ | 1783751135847251968 |
---|---|
author | Assi, Rita Masri, Nohad Dalle, Iman Abou El-Cheikh, Jean Ghanem, Hady Bazarbachi, Ali |
author_facet | Assi, Rita Masri, Nohad Dalle, Iman Abou El-Cheikh, Jean Ghanem, Hady Bazarbachi, Ali |
author_sort | Assi, Rita |
collection | PubMed |
description | Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Despite good responses to standard of care frontline chemoimmunotherapy, the prognosis of relapsed/refractory (R/R) patients remains obscured by the possible inadequate responses to salvage therapy, eligibility for autologous transplantation, age and comorbidities. Polatuzumab vedotin is an antibody-drug conjugate formed by a CD79b antibody conjugated to the highly cytotoxic agent monomethyl auristatin E by means of a cleavable linker. Following significant clinical efficacy in R/R DLBCL, polatuzumab vedotin was granted accelerated Food and Drug Administration (FDA) approval in combination with bendamustine plus rituximab for patients who have failed at least two prior therapies. Other clinical studies involving polatuzumab vedotin in combination with other therapy regimens are also under evaluation for previously untreated DLBCL patients. In this article, we review the different phases from the preclinical development of polatuzumab vedotin to studies leading to its first approval, and highlight the potential future roles of this molecule in the treatment landscape of DLBCL. |
format | Online Article Text |
id | pubmed-8432323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Atlantis Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-84323232021-09-29 Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma Assi, Rita Masri, Nohad Dalle, Iman Abou El-Cheikh, Jean Ghanem, Hady Bazarbachi, Ali Clin Hematol Int Review Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Despite good responses to standard of care frontline chemoimmunotherapy, the prognosis of relapsed/refractory (R/R) patients remains obscured by the possible inadequate responses to salvage therapy, eligibility for autologous transplantation, age and comorbidities. Polatuzumab vedotin is an antibody-drug conjugate formed by a CD79b antibody conjugated to the highly cytotoxic agent monomethyl auristatin E by means of a cleavable linker. Following significant clinical efficacy in R/R DLBCL, polatuzumab vedotin was granted accelerated Food and Drug Administration (FDA) approval in combination with bendamustine plus rituximab for patients who have failed at least two prior therapies. Other clinical studies involving polatuzumab vedotin in combination with other therapy regimens are also under evaluation for previously untreated DLBCL patients. In this article, we review the different phases from the preclinical development of polatuzumab vedotin to studies leading to its first approval, and highlight the potential future roles of this molecule in the treatment landscape of DLBCL. Atlantis Press 2021-03-13 /pmc/articles/PMC8432323/ /pubmed/34595463 http://dx.doi.org/10.2991/chi.k.210305.001 Text en © 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). |
spellingShingle | Review Assi, Rita Masri, Nohad Dalle, Iman Abou El-Cheikh, Jean Ghanem, Hady Bazarbachi, Ali Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma |
title | Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma |
title_full | Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma |
title_fullStr | Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma |
title_full_unstemmed | Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma |
title_short | Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma |
title_sort | polatuzumab vedotin: current role and future applications in the treatment of patients with diffuse large b-cell lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432323/ https://www.ncbi.nlm.nih.gov/pubmed/34595463 http://dx.doi.org/10.2991/chi.k.210305.001 |
work_keys_str_mv | AT assirita polatuzumabvedotincurrentroleandfutureapplicationsinthetreatmentofpatientswithdiffuselargebcelllymphoma AT masrinohad polatuzumabvedotincurrentroleandfutureapplicationsinthetreatmentofpatientswithdiffuselargebcelllymphoma AT dalleimanabou polatuzumabvedotincurrentroleandfutureapplicationsinthetreatmentofpatientswithdiffuselargebcelllymphoma AT elcheikhjean polatuzumabvedotincurrentroleandfutureapplicationsinthetreatmentofpatientswithdiffuselargebcelllymphoma AT ghanemhady polatuzumabvedotincurrentroleandfutureapplicationsinthetreatmentofpatientswithdiffuselargebcelllymphoma AT bazarbachiali polatuzumabvedotincurrentroleandfutureapplicationsinthetreatmentofpatientswithdiffuselargebcelllymphoma |